These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 38660145)

  • 21. Immunotherapeutic Approaches in Malignant Pleural Mesothelioma.
    Terenziani R; Zoppi S; Fumarola C; Alfieri R; Bonelli M
    Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34199722
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative effectiveness of second-line immune checkpoint inhibitor therapy versus chemotherapy for malignant pleural mesothelioma.
    Kim RY; Li Y; Marmarelis ME; Vachani A
    Lung Cancer; 2021 Sep; 159():107-110. PubMed ID: 34320420
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma.
    Rovers S; Janssens A; Raskin J; Pauwels P; van Meerbeeck JP; Smits E; Marcq E
    Biomedicines; 2022 Mar; 10(3):. PubMed ID: 35327475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The next generation of immunotherapy: keeping lung cancer in check.
    Somasundaram A; Burns TF
    J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is there a role for immunotherapy in malignant pleural mesothelioma?
    Tartarone A; Lerose R; Aieta M
    Med Oncol; 2018 May; 35(7):98. PubMed ID: 29845408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743.
    Scherpereel A; Antonia S; Bautista Y; Grossi F; Kowalski D; Zalcman G; Nowak AK; Fujimoto N; Peters S; Tsao AS; Mansfield AS; Popat S; Sun X; Lawrance R; Zhang X; Daumont MJ; Bennett B; McKenna M; Baas P
    Lung Cancer; 2022 May; 167():8-16. PubMed ID: 35367910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy in Malignant Pleural Mesothelioma.
    de Gooijer CJ; Borm FJ; Scherpereel A; Baas P
    Front Oncol; 2020; 10():187. PubMed ID: 32154179
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol.
    Shah R; Klotz LV; Chung I; Feißt M; Schneider MA; Riedel J; Bischoff H; Eichhorn ME; Thomas M
    Clin Lung Cancer; 2021 Mar; 22(2):142-146. PubMed ID: 33158765
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape.
    Dagogo-Jack I; Madison RW; Lennerz JK; Chen KT; Hopkins JF; Schrock AB; Ritterhouse LL; Lester A; Wharton KA; Mino-Kenudson M; Danziger N; Hung YP; Mata DA; Ross JS
    JCO Precis Oncol; 2022 Jun; 6():e2100422. PubMed ID: 35704798
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Traditional Treatment Approaches and Role of Immunotherapy in Lung Malignancy and Mesothelioma.
    Tamanna MT; Egbune C
    Cancer Treat Res; 2023; 185():79-89. PubMed ID: 37306905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sarcomatoid malignant pleural mesothelioma treated with nivolumab: A case series.
    Hashimoto K; Ozasa H; Yoshizawa A; Yoshida H; Ogimoto T; Hosoya K; Yamazoe M; Ajimizu H; Funazo T; Yoshida H; Sakamori Y; Hirai T
    Oncol Lett; 2022 Nov; 24(5):402. PubMed ID: 36276492
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma.
    Haakensen VD; Nowak AK; Ellingsen EB; Farooqi SJ; Bjaanæs MM; Horndalsveen H; Mcculloch T; Grundberg O; Cedres SM; Helland Å
    J Transl Med; 2021 May; 19(1):232. PubMed ID: 34059094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune checkpoint inhibitors a new player in the therapeutic game of mesothelioma: New reality with new challenges.
    Parikh K; Hendriks LEL; Bironzo P; Remon J
    Cancer Treat Rev; 2021 Sep; 99():102250. PubMed ID: 34174669
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repurposing therapeutics for malignant pleural mesothelioma (MPM) - Updates on clinical translations and future outlook.
    Kulkarni NS; Gupta V
    Life Sci; 2022 Sep; 304():120716. PubMed ID: 35709894
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigation of pd-l1 (cd274), pd-l2 (pdcd1lg2), and ctla-4 expressions in malignant pleural mesothelioma by immunohistochemistry and real-time polymerase chain reaction methods.
    Sule Kutlar Dursun F; Alabalik U
    Pol J Pathol; 2022; 73(2):111-119. PubMed ID: 36172747
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
    Forest F; Patoir A; Dal Col P; Sulaiman A; Camy F; Laville D; Bayle-Bleuez S; Fournel P; Habougit C
    Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future.
    Nicolini F; Bocchini M; Bronte G; Delmonte A; Guidoboni M; Crinò L; Mazza M
    Front Oncol; 2019; 9():1519. PubMed ID: 32039010
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nivolumab for the treatment of unresectable pleural mesothelioma.
    Hotta K; Fujimoto N; Kozuki T; Aoe K; Kiura K
    Expert Opin Biol Ther; 2020 Feb; 20(2):109-114. PubMed ID: 31825692
    [No Abstract]   [Full Text] [Related]  

  • 39. Malignant peritoneal mesothelioma: a review.
    Broeckx G; Pauwels P
    Transl Lung Cancer Res; 2018 Oct; 7(5):537-542. PubMed ID: 30450291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma.
    Quispel-Janssen J; van der Noort V; de Vries JF; Zimmerman M; Lalezari F; Thunnissen E; Monkhorst K; Schouten R; Schunselaar L; Disselhorst M; Klomp H; Hartemink K; Burgers S; Buikhuisen W; Baas P
    J Thorac Oncol; 2018 Oct; 13(10):1569-1576. PubMed ID: 29908324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.